Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial

Table 4 Changes in Cardiopulmonary Exercise Tests

	Vitamin D	Placebo	p-value	Corrected model p-value	Vitamin D CI (lower)	Vitamin D CI (higher)
Peak VO₂ ml/kg/min	−1.7 ± 3.4	0.4 ± 3.5	0.12	0.30	−3.2	−0.21
Peak METS	−0.5 ± 1.1	−0.2 ± 0.7	0.43	0.32	−0.9	0.03
Peak Tidal Vol	30 ± 380	−40 ± 240	0.55	0.72	−132.5	195.3
CRI	0.1 ± 0.20	0 ± 2.9	0.009*	0.17	0.02	0.24
V_E Slope	3.0 ± 6.7	0.8 ± 5.7	0.36	0.51	0.1	5.9
Heart Composite	0.3 ± 0.7	0.1 ± 0.6	0.32	0.57	0.28	0.36
Pulmonary Vascular Score	0.1 ± 0.5	0.1 ± 0.6	0.97	0.34	−0.1	0.4
Deconditioning Score	0.3 ± 0.6	0.2 ± 0.7	0.65	0.19	0.03	0.53
PETCO2(mmHg)	−1.6 ± 3.4	−0.6 ± 1.9	0.30	0.40	−3.1	−0.11
Shape Score	0.1 ± 1.6	0.3 ± 1.0	0.65	0.71	−0.6	0.8
Peak RER	0.1 ± 0.3	−0 ± 0.1	0.26	0.44	0	0.24
OUES	−0.1 ± 0.4	−0.3 ± 0.5	0.12	0.32	−0.14	0.36

Data are expressed as Δ ± SD, 95% CI)
Abbreviations: Standard Deviation (SD), Confidence Interval (CI), Volume of oxygen consumed (VO ₂), metabolic equivalents (METS), volume (Vol), Ventilatory Efficiency (V _E), Respiratory Exchange Ratio (RER), Oxygen Uptake Efficiency Slope (OUES)
^*Using Mann-Whitney

ISSN: 1471-2261